| Summary: | <p><strong>Objective:</strong> to study the efficacy, tolerability, and safety of Artradol in patients with knee osteoarthrosis.</p><p><br /><strong>Subjects and methods.</strong> The investigation enrolled 35 patients of both sexes, mean age 63,45 ± 6,9 years, with stages II and III gonarthrosis<br />and walking pain intensity > 40 mm visual analog scale. All the patients were given Artradol (chondroitin sulfate) intramuscularly every other day in a dose of 0,1 g (the first 3 injections), its fourth injection was 0,2 g used for 2 months. Changes in the WOMAC index, up-and-go test, as well as the need to use nonsteroidal anti-inflammatory drugs (NSAIDs), and therapeutic efficiency as viewed by the physician and patient were estimated.</p><p><br /><strong>Results.</strong> The clinical effect of the drug occurred by the average treatment day of 18. Lower needs for NSAIDs were noted in 97 % of the patients;<br />NSAIDs were discontinued in 22 (62 %) cases. There was a statistically significant decrease in the total scores of the WOMAC and up-to-go tests on therapy completion. The therapy resulted in considerable improvement in 97,0 % of the patients.</p><p><br /><strong>Conclusion.</strong> Artradol has high clinical efficacy and safety and a noticeable delayed-acting symptom-modifying effect, which makes it relevant for use in the treatment of gonarthrosis.</p>
|
|---|
